Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022;24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
Ava Ferguson Bryan, MD, AM, Elizabeth Yates, MD, MPH, and Neelima Tummala, MD, MSc
The health sector has obligations and ample opportunities to protect health by decreasing waste and motivating more system-wide sustainable clinical practices.
AMA J Ethics. 2022;24(10):E927-933. doi:
10.1001/amajethics.2022.927.
Monitoring surgeons’ capacities over time are rooted in professional duties to protect patients’ safety. Aging surgeons should undergo assessments and be encouraged to stop practicing before their diminished skill becomes too risky.
AMA J Ethics. 2016;18(10):986-992. doi:
10.1001/journalofethics.2016.18.10.ecas2-1610.